In the published article, there was an error in the author list, and author “on behalf of Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC)” was erroneously excluded. The corrected author list appears below.
Águeda Molinos-Quintana1*, Anna Alonso-Saladrigues2*, Blanca Herrero3, Teresa Caballero-Velázquez4, Víctor Galán-Gómez5, Melissa Panesso6, Montserrat Torrebadell2, Javier Delgado-Serrano4, Concepción Pérez de Soto1, Anna Faura2, Berta González-Martínez5, Ana Castillo-Robleda3, Cristina Diaz-de-Heredia6, Antonio Pérez-Martínez5, José María Pérez-Hurtado1, Susana Rives7,8, José Antonio Pérez-Simón4 on behalf of Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC)
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
B cell aplasia, late B-cell recovery, pre-infusion tumor burden, CD19 CART-cells, relapsed/refractory acute lymphoblastic leukemia, tisagenlecleucel, B-cell monitoring
Citation
Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives S and Pérez-Simón JA (2024) Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring. Front. Immunol. 15:1373852. doi: 10.3389/fimmu.2024.1373852
Received
20 January 2024
Accepted
25 January 2024
Published
07 February 2024
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
15 - 2024
Updates
Copyright
© 2024 Molinos-Quintana, Alonso-Saladrigues, Herrero, Caballero-Velázquez, Galán-Gómez, Panesso, Torrebadell, Delgado-Serrano, Pérez de Soto, Faura, González-Martínez, Castillo-Robleda, Diaz-de-Heredia, Pérez-Martínez, Pérez-Hurtado, Rives and Pérez-Simón.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Águeda Molinos-Quintana, agueda.molinos.sspa@juntadeandalucia.es; aguedamolinos@hotmail.com; Anna Alonso-Saladrigues, anna.alonso@sjd.es
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.